



Europass Curriculum Vitae

Personal information

First name(s) / Surname(s)	Espín Balbino, Jaime	
Address(es)	Campus Universitario de Cartuja. Cuesta del Observatorio, 4 Apdo Correos 2070. 18080 Granada- Spain	
Telephone(s)	+34 958027400	Mobile: +34670944108
Fax(es)	+34 958027504	
E-mail	jaime@easp.es jaime.espin.easp@juntadeandalucia.es	
Nationality	Spanish	
Date of birth	18/04/1973	
Gender	Male	

Work experience

Dates	July 1997- up to now (except one academic year 98-99 in the University of California as Visiting Graduate Student)
-------	--

Occupation or position held	Professor, Researcher and Consultant
-----------------------------	---

Main activities and responsibilities	As Professor : Teach (in the Master of Public Health, Master of Health Economics, etc.) and coordinate teaching activities (Course of Health Technology Assessment, Economics Evaluations, etc) from 1999.
--------------------------------------	---

As **Researcher**

- **Principal Investigator** – Work Package 6 - FP7- HEALTH-2012.3.2-2 – New methodologies for health technology Assessment - Advancing and strengthening the methodological tools and practices relating to the application and implementation of Health Technology Assessment (HTA) (2013-2017).
- **Principal Investigator** – Work Package 5 - FP7-HEALTH.2013.4.1-6: Mapping chronic non-communicable diseases research activities
- **Member of the Steering Committee**. EU-WHO project - Research agenda for the EU on Health Economic Evaluation
- **Researcher and Member of the Management Committee** - COST - IS0903: Enhancing the role of medicine in the management of European health (2009-2013)
- **Researcher** - Public Health Programme: Public Health Law to Support Pandemic Influenza Preparedness – PHLawFLU (2007-2009)

As **Consultant** (main projects):

* **Deputy Director** – EMINet – European Medicines Information Network.

The EMINet project – European Medicines Information Network on Pricing and Reimbursement of pharmaceuticals – was launched in December 2008 and is co-funded by the European Commission (DG Enterprise and Industry) until December 2012. It aims to support EU Member States, EEA-EFTA countries and the Commission by providing information, technical expertise and analysis on

pharmaceutical pricing and reimbursement policies and related topics.

*** Project Manager**

Study on Differences and commonalities in pricing and reimbursement systems in Europe. The objective of this study is to carry out a synthesized and structured analysis on existing pricing and reimbursement systems and cost containment practices in place in 25 Member States
Study in : http://ec.europa.eu/enterprise/phabiocom/comp_pf_en.htm
Institution - European Commission – DG Enterprise

*** International independent expert in the Working Group on Pricing of the Pharmaceutical Forum**

The Pharmaceutical Forum is a high-level political platform for discussion supported by a Steering Committee and three expert Working Groups. The aim is to improve the performance of the pharmaceutical industry in terms of its competitiveness and contribution to social and public health objectives. The Forum brings together Ministers from all European Member States, Representatives of the European Parliament, the Pharmaceutical industry, health care professionals, patients and insurance funds

*** Observer in the Pharmaceutical Pricing and Reimbursement Information –PPRI- project**

PPRI is a project funded by the European Commission, Health and Consumer Directorate-General and co-funded by the Austrian Federal Ministry for Health and Women's Issues. The objective of the PPRI project is to provide knowledge and information on pharmaceutical systems in the European Union.

*** Team Leader**

Project "Technical Assistance in Public and Environmental Health in Bosnia and Herzegovina" (financed by the European Union – 1,125,000 Euros), where the wider objectives were to enhance the health status of the population through the support of efficient and sustainable public health and environmental health functions within the framework of the health care reform. This project designed an Integrated Public Health Plan (IPHP) for the country.

The main functions were:

- Management and execution of the project and the organization, supervision and coordination of the diverse components and activities of the Project, according to the established in the terms of reference.
- Person in charge of the general administration and management technical-financial and of human resources of the project, including the purchase of equipment (through tender procedures) and selection of local experts, according to PHARE regulations and to the specific rules for Bosnia-Herzegovina.
- Chairman of the evaluation committee of the tenders (245.000 Euros) and of the Health Promotion Actions financed by grants to 6 NGOs by special restricted procedure

*** Technical Assistant**

Evaluation of the European Union Cooperation with Latin America in Health (IB/AMS/272)", financed by the European Union

Assistant to the preliminary meeting of the project (Brussels, 14 and 15 October of 1999). Assistant in the tasks of the phase I of the project: Inventory and documents revision (Brussels, of the 3 at the 12 and of the 15 at November 19 1999). Assistant in preliminary meeting of the phase II (San José de Costa Rica, 27 to 31 March) Assistant in the realization of each Reports. Reports in http://ec.europa.eu/europeaid/how/evaluation/evaluation_reports/2000/951525_docs_en.htm

Name and address of employer

Escuela Andaluza de Salud Pública – Andalusian School of Public Health
Campus Universitario de Cartuja. Cuesta del Observatorio, 4
Apdo. Correos 2070. Granada 18080. Spain

Education and training

Dates	July 2011
Principal subjects/occupational skills covered	Visiting Professor
Name and type of organisation providing education and training	Duke University – Fuqua Business School
Dates	July 2011
Principal subjects/occupational skills covered	Visiting Research
Name and type of organisation providing education and training	University of Chicago – The Center for Health and Social Sciences
Dates	May 2011
Principal subjects/occupational skills covered	PhD in Health Economics and Pharmaceutical Policies
Name and type of organisation providing education and training	University of Granada
Dates	August 2007
Principal subjects/occupational skills covered	Program “Measurement, design, and analysis methods for health outcomes research”
Name and type of organisation providing education and training	Harvard School of Public Health. Harvard University
Dates	2001-2003
Title of qualification awarded	Master in Health Economics and Management of Health Institutions
Name and type of organisation providing education and training	Escuela Andaluza de Salud Pública – Andalusian School of Public Health
Dates	1998-1999
Title of qualification awarded	Visiting Research Graduate Fellow. Department of Economics
Principal subjects/occupational skills covered	International Economy
Name and type of organisation providing education and training	University of California, Santa Barbara (EE.UU)
Dates	1996-1998
Title of qualification awarded	Master of Business Administration (MBA)
Name and type of organisation providing education and training	Escuela de Negocios de Andalucía (Esna)

Dates 1991-1996
 Title of qualification awarded Bachelor's Degree in Law. LLB.
 Name and type of organisation providing education and training University of Granada.

Personal skills and competences

Mother tongue(s) **Spanish**

Other language(s)

Self-assessment

European level (*)

English

French

	Understanding		Speaking		Writing
	Listening	Reading	Spoken interaction	Spoken production	
English	B-2	C 1	B2	B2	B2
French	A1	A2	A1	A1	A1

(*) Common European Framework of Reference for Languages

Social skills and competences Mainly, good ability to adapt to multicultural environments, gained though my work experience abroad.

Organisational skills and competences Good experience in project and team management.

Technical skills and competences Good level in computer (see below)

Computer skills and competences Good command of Microsoft Office™ tools (Word™, Excel™ and PowerPoint™);

Artistic skills and competences

Other skills and competences

Driving licence Car and motorbike driving licence

Additional information

Annexes Publications

Books

Espín-Balbino, Jaime. El sector farmacéutico y los medicamentos en la Unión Europea: Una aproximación a los retos actuales. 2004. Granada

Espín Balbino J, Abellán Perpiñán JM, Peiró Moreno S, Gómez Pajuelo P. Garantía, Solvencia y Sostenibilidad del Sistema Nacional de Salud Español: Análisis Cualitativo desde la Farmacia Hospitalaria. Madrid: Fundación Gaspar Casal; 2013. [ISBN: 84-695-7549-X]

Chapters (Book)

Rovira Fornes, Joan; Espín Balbino, Jaime. Acceso, Financiación y Regulación Económica de los Medicamentos (En Medicamentos. Entre la Salud y el Mercado). Icaria 2009

Espín Balbino, Jaime. La Regulación Económica de los Medicamentos y el Comercio Paralelo En La Unión Europea (En Barranco Vela, R. (Dir.): "El acceso al medicamento. Retos jurídicos actuales, intervención pública y su vinculación al derecho a la salud"(coord. F. M. Bombillar Sáenz), Comares, Granada, 2009

Espín, Jaime; Oliva, Juan; Rodríguez-Barrios, José Manuel. Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: los acuerdos de riesgo compartido (En Puig Junoy, J. Lecturas sobre economía del sector biofarmacéutico. Editorial Springer Healthcare. Noviembre 2012. ISBN 9788494011849)

Journals

Molina-Montes E, Perez-Nevot B, Pollán M, Sanchez-Cantalejo E, Espín J, Sanchez MJ. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis, *The Breast* (2014), <http://dx.doi.org/10.1016/j.breast.2014.10.005>. FI: 2.581. Q: 1

Molina-Montes E, Requena M, Sánchez-Cantalejo E, F. Fernández M, Arroyo-Morales M, Espín J, P. Arrebola J, Sánchez MJ. Risk of second cancers cancer after a first primary breast cancer: A systematic review and metaanalysis, *Gynecol Oncol* (2014), <http://dx.doi.org/10.1016/j.ygyno.2014.10.029>. FI: 3.687. Q: 1

Rovira, J; Lindner, L; Giménez, E; Espín, J; Olry de Labry, A; García, L; Biosimilars in the European market. *Generics and Biosimilars Initiative Journal (GaBI Journal)*. 2013;2(1):30-5.

Leopold C, Vogler S, Habl C, Mantel-Teeuwisse AK, Espin J, Personalised medicine as a challenge for public pricing and reimbursement authorities - survey among 27 European countries on the example of trastuzumab, *Health Policy* (2013). <http://dx.doi.org/10.1016/j.healthpol.2013.09.018> FI: 1.725. Q: 2

Olry de Labry Lima A, Moya Garrido M, Espín Balbino J. Systematic review of economic evaluation studies and budget impact on ambulatory monitoring of capillary glucose in type 2 diabetics.. *Prim Care Diabetes*, 2014; (8): 13-21
FI: 1,289 Q: 3 PMID: 24360230
<http://dx.doi.org/10.1016/j.pcd.2013.11.005>

Espín J. Innovando en la gestión del gasto farmacéutico: del pago por producto al pago por resultados en salud. *Rev Esp Salud Pública* 2013; 87 (4): 303-305. FI: 0,706 Q: 4

Olry de Labry A, Espín J, García Valero J. Diferencias entre consumo observado y recomendado de las tiras reactivas para la monitorización ambulatoria de la glucosa capilar en España. *Pharmacoecoon Span Res Artic*. 2013. FI: 3,338 Q: 1.
<http://dx.doi.org/10.1007/s40277-013-0021-8>

Ilinca, Stefania; Hamer, Susan; Botje, Daan; Espin, Jaime; Mendes, Rita Veloso; Mueller, Jani; van Wijngaarden, Jeroen; Vinot, Didier; Plochg, Thomas. All you need to know about innovation in healthcare: The 10 best reads. *International Journal of Healthcare Management*, Volume 5, Number 4, October 2012 , pp. 193-202(10)

Cabrera-León A; Jadad AR; Nuño-Solinís R; Bernabéu-Wittel M; Morales-Asencio J; Valdivieso-Martínez B; Fernández-Miera MF; Sampedro-García I; March-Cerdá JC; Gosálvez-Prados D; Espín J. Improving care for people living with chronic diseases: Innovative examples from Spain. *International Journal of Healthcare Management* 2012; 5(4): 208-215

AO de Labry Lima, D Epstein, LG Mochón, JR Aragón, J Espín. Análisis de coste-efectividad de la prueba de citología cervicovaginal. *Prog Obstet Ginecol*. 2012.
<http://dx.doi.org/10.1016/j.pog.2012.02.006>

Epstein DM, Garcia-Mochon L, Espin J, Soares M. Use of Multiparameter Evidence Synthesis to Assess the Appropriateness of Data and Structure in Decision Models. *Medical Decision Making*. 2013 Mar 29. FI: 2.698. Q: 1

Epstein D, Olry Labry A, García-Mochón L, Espin J, Esquivias J. A comparison of the accuracy of liquid cytology versus conventional screening: a meta-analysis of split-sample studies. *Journal of the Royal Statistical Society Series A (Statistics in Society)*. 7.Feb 2013. FI: 1,573 Q: 1

Martin R, Conseil A, Longstaff A, Kodo J, Siegert J, Duguet AM, Lobato de Faria P, Haringhuizen G, Espin J, Coker R. Pandemic influenza control in Europe and the constraints resulting from incoherent public health laws. *BMC Public Health*. 2010 Sep 3; 10:532. FI: 2.364. Q: 2

Espín, Jaime; Oliva, Juan; Rodríguez-Barrios, José Manuel. Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: los acuerdos de riesgo compartido. *Gac Sanit*. 2010;24:491-7. - vol.24 núm 06. 10.1007/s40277-013-0021-8. FI: 1.114. Q: 3

Sabine Vogler, Jaime Espin and Claudia Habl. Pharmaceutical Pricing and Reimbursement Information (PPRI) – New PPRI analysis including Spain. *Pharmaceutical Policy and Law*. Volumen: 11 Pages – 213- 234. 2009

Rovira Joan, Espin Jaime. Fraud in pharmaceuticals. *Pharmaceutical Policy and Law*. Volumen 11. Pages 161-171. 2009

L. Lindner*, E. Gimenez, J. Rovira, J. Espin, A. Olry, G. Leticia. Biosimilars in the European Market. Value in Health. Volume 14, Issue 7, Page A338, November 2011

AO de Labry Lima, D Epstein, LG Mochón, JR Aragón, J Espín. Análisis de coste-efectividad de la prueba de citología cervicovaginal. Prog Obstet Ginecol. 2012. doi:10.1016/j.pog.2012.02.006

Reports / Policy Papers

Espín Balbino J, García-Mochón L. Evaluación económica de los sistemas de monitorización de cetonas en sangre para el diagnóstico y prevención de la cetoacidosis. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía; Madrid: Ministerio de Sanidad y Consumo, 2009. ISBN: 978-84-96990-47-0

Espín J, Rovira J. Analysis of differences and commonalities in pricing and reimbursement systems in Europe. A study funded by DG Enterprise and Industry of the European Commission, EASP Final Report, June 2007. Disponible en: http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/pricing-reimbursement/national-systems/index_en.htm

Espin J, Rovira J, Olry de Labry A. Review series on pharmaceutical pricing policies and interventions: Working paper 1: External reference pricing. WHO Policy Review 2011

Rovira J, Espin J, Garcia L, Olry de Labry A. The impact of biosimilars' entry in the EU market. (European Medicines Information Network –EMINET- 2011). DG Enterprise and Industry. European Commission. Disponible en http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/monitoring/index_en.htm

Kanavos P, Nicod E, Espin J, van den Aardweg S. Short- and Long-Term Effects of Value-Based Pricing vs. External Price Referencing, (European Medicines Information Network –EMINET- 2011). DG Enterprise and Industry. European Commission. Disponible en http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/pricing-reimbursement/national-systems/index_en.htm

Espin J, Rovira J, Garcia L. Experiences and Impact of European Risk-Sharing Schemes Focusing on Oncology Medicines. (European Medicines Information Network –EMINET- 2011). DG Enterprise and Industry. European Commission. Disponible en http://ec.europa.eu/enterprise/sectors/healthcare/competitiveness/pricing-reimbursement/national-systems/index_en.htm

Editor

Organización Panamericana de la Salud. El acceso a los medicamentos de alto costo en las Américas: Contexto, Desafíos y Perspectivas. Documento N°1 Serie Técnica de Medicamentos Esenciales, Acceso e Innovación. Washington 2009. (En Ingles: Pan America Health Organization. Access to High-Cost Medicines in the Americas: Situation, Challenges and Perspectives. Technical Series No. 1 Essential Medicines, Access, and Innovation. Washington 2010)

Organization Panamericana de la Salud. Guía para la Implementación de Estrategias de Medicamentos Genéricos en los países de América Latina y el Caribe como Mecanismo para Mejorar el Acceso a los Medicamentos. Documento N°3 Serie Técnica de Medicamentos Esenciales, Políticas Farmacéuticas. Washington 2011.